WALTHAM, Mass., April 5, 2011 (GLOBE NEWSWIRE) -- BG Medicine (Nasdaq:BGMD) today announced the launch of its @galectin3 Twitter handle and galectin-3 Facebook fan page in an effort to raise awareness of galectin-3, a protein that has been shown to play an important role in the development and progression of heart failure. The launch of the social media platforms coincides with the American College of Cardiology 60th Annual Scientific Session (ACC.11) in New Orleans.
In November 2010, the FDA cleared the company's Galectin-3 test for use as an aid in the assessment of prognosis in patients with chronic heart failure. Studies suggest that 30% or more of patients with chronic heart failure may have elevated levels of galectin-3. This galectin-3 mediated form of heart failure is associated with progressive fibrosis of the heart muscle, which impairs the heart's ability to pump.
"Galectin-3 seems to be attracting a lot of attention in the scientific community with approximately 60 papers in the first quarter of this year alone and nearly 1,500 papers since the first publication in 1988," said Pieter Muntendam, MD, president and CEO of BG Medicine. "Our Twitter and Facebook presence offers a convenient way for scientists and clinicians to follow the scientific developments of galectin-3."
Galectins are a group of proteins that bind to a class of carbohydrates know as beta-galactosides. Galectins play an important and complex role in intracellular pathways and disease mechanisms. Since 1994, scientists working in the field of carbohydrate-binding proteins have so far identified a total of 15 galectins.
About BG Medicine Inc.
BG Medicine is a life sciences company focused on the discovery, development and commercialization of novel diagnostics based on biomarkers to improve patient outcomes and contain healthcare costs.
The BG Medicine Inc. logo is available at
Forward Looking Statements
This press release may contain forward-looking statements which are made pursuant to the safe harbor provisions of Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified by the use of forward-looking terminology such as "will", "would", "should", "is designed to", "expects", "confident", "aims", "anticipates", "intends", "plans", "believes", "may", "estimates", "predicts", "projects", or the negative thereof or variations thereof or similar expressions intended to identify forward-looking statements. These statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond the Company's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. Disclosures regarding the risks and uncertainties faced by the Company are contained in our public filings with the Securities and Exchange Commission, including the Company's most recent Annual Report on Form 10-K under the heading "Risk Factors", which is available on the Company's investor relations website at and on the SEC's website at .
CONTACT: Michael W. Rogers EVP & Chief Financial Officer (781) 890-1199